Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Conditions
Interventions
5 mg Serlopitant Tablets
Matching Placebo Tablets
Locations
39
United States
Study Site 130
Los Angeles, California, United States
Study Site 128
Mission Viejo, California, United States
Study Site 123
San Diego, California, United States
Study Site 127
San Jose, California, United States
Study Site 131
Stockton, California, United States
Study Site 106
Colorado Springs, Colorado, United States
Start Date
October 3, 2017
Primary Completion Date
August 15, 2018
Completion Date
September 6, 2018
Last Updated
May 20, 2021
NCT05599191
NCT05733533
NCT05628740
NCT02349425
Lead Sponsor
Vyne Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions